Recursion, a clinical-stage TechBio company, is set to present preliminary data from its Phase 1b/2 clinical trial, TUPELO, at the 2025 Digestive Disease Week (DDW) meeting on May 4, 2025, in San ...

Los Angeles—Artificial intelligence (AI)-based drug discovery continues to tout accelerated timelines and novel and effective treatments, yet today’s clinical success rates remain at a low 10%. On ...

Scaling state-of-the-art models for real-world deployment often requires training different model sizes to adapt to various computing environments. However, training ...

Recursion Pharmaceuticals announced results of a clinical trial for its lead drug candidate Tuesday that, while a success on paper, likely won’t satisfy many investors closely watching the AI drug ...

Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud.

To speed up computation, deep neural networks (DNNs) usually rely on highly optimized tensor operators. Despite the effectiveness, tensor operators are often defined empirically with ad hoc semantics.